ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.
The US Food and Drug Administration announced a proposal to remove oral phenylephrine – a common ingredient in many popular ...
The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...
The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...
An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...
The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.
The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.
The selling price is an indication that the FDA’s planned sunsetting of the rare pediatric disease voucher program may be ...
GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback